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ABSTRACT 
A chemically-preserved oral antihistaminic suspension based on fexofenadine as an active pharmaceutical ingredient and preserved with 
aminobenzoic acid esters (parabens) was found contaminated with Burkholderia cepacia (B. cepacia). This finding was detected only after six 
months from manufacturing. The bacterial count increased from 10, after six months, to 1475 Colony Forming Unit (CFU)/ml after nine months. The 
organism constituted continually increasing the hazard to the users long after passing undetected to the market. The current finding highlighted the 
importance of both appropriate neutralization method of the preservatives in the preservative efficacy test and the sensitivity of the method of 
bioburden enumeration and detection. 
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INTRODUCTION 
Pharmaceutical product preservation is an important aspect for 
drugs with high water activity, in order to protect them from 
microbial spoilage. Aminobenzoic acid esters (parabens) are very 
common preservatives that are used in the field of non-sterile 
dosage forms. Elder and Crowley [1] discussed that parabens are 
more active against Gram-positive, than Gram-negative bacteria and 
more active against yeasts and molds than bacteria. The activity 
increases with increased alkyl chain length (butyl>propyl> 
ethyl>methyl), but the aqueous solubility commensurately 
decreases, and consequently the parabens are also often used in 
combination, e. g. methyl and propyl paraben. Parabens also show 
some synergy with ethylene diamine tetraacetic acid (EDTA)[2]. 
CASE REPORT 
A pharmaceutical liquid oral dosage form containing non-sedating 
antihistaminic compound fexofenadine as an active pharmaceutical 
ingredient (API) and a mixture of methyl and propyl parabens as 
preservatives. The finished product was found to be clean 
microbiologically when examined directly after manufacturing. The 
product was packaged in 100 ml dark amber colored glass containers 
with white screw caps. Other ingredients included Xanthan gum, 
Disodium Edetate, Sucrose, Sorbitol solution, Poloxamer, Sodium 
Phosphate Monobasic, Sodium Phosphate Dibasic and Raspberry 
Flavor. The product showed no growth in Tryptone Soya Agar (TSA) 
when tested for the total viable aerobic count (TVAC) according to the 
United States Pharmacopeia (USP)<61>[3] with results less than ten 
Colony Forming Unit (CFU)/ml.  
The used culture media were verified for sterility and growth 
promotion ability as per USP<61>[3]. The laminar air flow (LAF) 
hood in which all tests were performed had passed all the 
engineering tests for air velocity, particulate and integrity tests 
using verified and calibrated measuring instruments. In addition, all 
the culture media incubators were calibrated, validated and 
continuously monitored by a validated chart recorder.  
Appropriate training and knowledge of operators were insured and 
verified for each test procedure. The sterility of the used media and 
aseptic handling was confirmed by the concurrent inclusion of 
negative control plates with test ones. Quality control (QC) of 
activity in LAF unit was performed by taking passive air sample 
through the whole activity and surface samples by contact plates 
from the bench as well as the two side walls of LAF unit to verify 
surface cleanliness.  
Samples from the manufactured batch were retained in calibrated 
and validated stability cabinets for both on-going and accelerated 
product stability testing with conditions of 30±2 °C/Relative 
Humidity (RH) % 65±5 and 40±2 °C/RH% 75±5; respectively [4]. All 
the chemical tests were within the accepted laboratory limits. The 
range of pH was 6.2-6.3, and the concentrations of Methyl and 
Propyl Parabens were 97.7-105.7% and 94.6-104.4 %, respectively, 
during the course of study. The microbiological count test was 
acceptable either accelerated or on-going with TVAC less than and 
ten Colony Forming Unit (CFU)/ml at three and six months stability 
points, respectively. However, at nine months of on-going stability 
point the microbiological count raised at a relatively higher rate 
with TVAC of 1475 CFU/ml. The breaking point of the generation 
time for the bacteria was expected to be between 3-6 mo with an 
slow initial rate from 0-3 mo and fast one from 6-9 mo. Since no 
count was detected till the point of 6 mo, the generation time was 
estimated to be between 1.89 to 41.28 mo (56.67 to 1238.49 d) with 
the average middle point (5 CFU/ml) to be 6.28 mo (188.25 d). The 
initial lag phase length could not be determined. Meanwhile, the 
higher rate section was determined to have a generation time of 1.49 
mo (44.73 d). A simulated XY data study for less than ten CFU/ml 
count was performed using GraphPad Prism v 6.01 for Windows, 
and the result is illustrated in fig. 1. Based on a simulation study, the 
initial count was between 2 and 7 CFU/ml. The microorganism was 
identified by Gram stain and miniaturized biochemical identification 
system BBL CRYSTAL Enteric/Non-Fermenter (E/NF) as described 
by Eissa [5]. Its identification tests showed Gram-negative rods with 
negative Indole and Oxidase reactions; the identification (ID) profile 
referred to Burkholderia cepacia (B. cepacia).  
However, the organism passed the test of the specified 
microorganisms as described by USP<62>[6] because it was not 
included in the routine testing. The presence of B. cepacia was 
detected once in the water system of the manufacturing plant used for 
liquid products and identified among the routine tests of water but 
was not considered as an objectionable threat. The interesting 
behavior of this microorganism in the product required further 
investigation. A procedure that was performed by testing another 
microbiologically clean batch of the same product to perform 
antimicrobial efficacy test (AET) using an isolated B. cepacia and 
comparing it with a benchmark product of another company after 
testing its microbiological cleanliness. The formula of the benchmark 
included Propylene Glycol, Disodium Edetate, Propylparaben, 
Butylparaben, Xanthan Gum, Poloxamer 407, Titanium Dioxide, 
Sodium Phosphate Monobasic, Sodium Phosphate Dibasic. 
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Fig. 1: Microbial growth profile of Burkholderia cepacia 
observed in the non-sedating oral antihistaminic suspension 
medicinal product with initial half portion of the curve 
generated with different values of possible starting 
contamination from two to seven CFU/ml at zero time. (Graph 
generated by Microsoft Office Excel 2007) 
 
Artificial Raspberry Cream Flavor and Xylitol in amber glass bottle 
with plastic screw cap. Preliminary neutralization study was 
conducted first to ensure that the processing and dilution 
techniques could recover the low level of the microbial count from 
the tested products as shown in table 1. Results showed that all the 
tested organisms passed the test according to USP<61>[3] and Eissa 
and Norby criteria [7]. Interestingly, both formulae failed to pass the 
preservative efficacy test (PET) which was performed according to 
USP<51>[8] with the studied product showing greater failure rate 
than the benchmark product. The results showed that Gram-
negative bacteria were the most resistant to the preservation of both 
formulae notably B. cepacia and Escherichia coli.  
Both organisms actually increased in number after 14 ds to high to be 
count (HTBC) values indicating that these microorganisms got 
nutritional benefits from products rather than being suppressed or 
killed during the proposed period of testing. However, benchmark 
product showed greater activity on Staphylococcus aureus and 
Pseudomonas aeruginosa than the new oral suspension product 
viz.>1.65 vs. 0.69 and>0.61 vs. HTBC log reduction (LR); respectively. 
Interestingly both formulae passed the AET for fungi with the new 
product being more active than the benchmark viz. 3.6 vs. 1.2 LR for 
Candida albicans and 0.37 vs. 0.00 LR for Aspergillus brasiliensis. 
 Table 1: Preliminary neutralization study for the tested microorganisms against the two liquid non-sedating antihistaminic products 
 Oral antihistaminic 
microorganisms 
Incubation conditions Relative microbial recovery ratio (b) 
New product suspension Benchmark suspension 




Pseudomonas aeruginosa 1.56 0.64 
Escherichia coli 1.08 0.60 
Burkholderia cepacia 1.13 (a) 0.57 
Candida albicans 20-25 °C in 
SDA 
1.13 0.55 
Aspergillus brasiliensis 0.88 0.86 
(a)= Non pharmacopoeial microorganism included in the study from the isolated Gram-negative rod found in the new product. (b) = 0.3 Log10
 
 
variation (0.5) is the criteria of passing the test to account for plating variability.  
DISCUSSION 
The current case highlighted several critical situations in relation to 
medicinal product safety delivered to the final customer. First, the 
sensitivity of test should be reviewed by pharmaceutical firms to 
ensure maximum possible recovery and detection of specific 
microorganisms. This should not allow to overlook the criticality of 
the next point; PET. Secondly, the regulatory agencies are required 
to enforce pharmaceutical companies not to release drugs with 
significant water activity aw
Otherwise, an overestimated activity and safety will be incorrectly 
addressed with the result of the release of potentially unsafe drugs 
to the market. If the product did not catch the contamination from 
the manufacturing environment and/or the pharmaceutical water, it 
would do so from the final consumer. Consequently, it may turn 
harmful at the following administration as most of the non-sterile 
products are packaged in containers that lose physical integrity and 
separation from the surrounding environment and individuals once 
opened in the first time use. Finally, the possibility of the 
microorganism to be viable but not cultivable should not be 
underestimated. Thus it may be useful to use advanced technologies 
and techniques to detect its presence in the medicinal product. 
>0.6 except after providing a scientific 
justification for their products efficacy against test microorganisms 
in AET test [9]. In addition, each firm should include specific 
annoying bugs that are resistant to antimicrobials, isolated from 
their environment and water of the facility in their test 
microorganisms' spectrum. Such a procedure would confirm the 
product ability to stop these organisms from being a source of a 
hazard to users [10]. The observed growth after appreciably long lag 
phase provided an evidence of the ability of microorganisms to not 
only survive but proliferate in a hostile environment, causing harm 
to the final consumer upon contact especially those with specific 
disease conditions and with weak immune system populations. 
Thirdly, PET should be accompanied by a proper neutralization 
method in order not to exaggerate the potency of the antimicrobials 
in the tested pharmaceutical formulae [7].  
CONCLUSION 
The current case demonstrated the ability of very low level of 
contamination of B. cepacia to survive and proliferate in harsh 
environmental conditions in the presence of chemical antimicrobial 
compounds. In addition, it highlighted the importance of deploying 
an effective preservative efficacy program in complementation with 
sensitive bioburden detection techniques in order to not allow of 
skipping unwanted contamination to the final consumers.  
However, the annoying possibility of that microorganism may have 
been viable but not cultivable (VBNC) submitted warning alarm signal 
about the need to switch to rapid microbiological methods (RMM). 
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